Hamilton Robotics and Promega to Collaborate
News Aug 27, 2009
Hamilton Robotics and Promega Corporation announced today that the two companies will collaborate in the development of an automated system for the isolation of genomic DNA from large-volume blood samples.
Based on Hamilton’s MICROLAB® STAR liquid handling technology and Promega systems and reagents, the new offering will increase throughput for large-volume applications such as biobanking, pharmacogenomics and genetic research.
“Hamilton’s air displacement pipetting technology offers a number of unique advantages over other robotics systems,” explained Jeff Briganti, strategic marketing manager for Promega. “We have already successfully collaborated with them to create and optimize automated protocols for several applications. This collaboration takes the relationship one step further toward the codevelopment of an entire system.”
Although life science research has seen a recent overall trend toward miniaturization, several genetic analysis applications require the ability to isolate DNA from large sample volumes. Automated large-volume liquid handling poses specific challenges that Hamilton has been able to address, most recently with the introduction of its 5ml independent pipetting channels and 5ml disposable tips for the MICROLAB STAR platform.
Promega’s new method employs next-generation technology and novel chemistry, allowing for an automated process with increased recovery, higher concentration and enhanced purity of gDNA isolated from large-volume blood samples compared to previous automated techniques.
Hamilton and Promega expect to launch the new system later this year.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.